NEXT
Sign in to follow
Search Results

0 results for 'Axinn'

You can use to get even better search results Axinn
September 16, 2013 | Corporate Counsel

Obviousness in Medical Device Patent Litigation

Obviousness is almost invariably invoked as a defense in medical device patent litigation. Through an understanding of trends in the case law, medical device companies can gain a leg up on the competition when litigating patent obviousness in court.
8 minute read
February 26, 2004 | New York Law Journal

New Deals

New York firms were in the thick of a bidding war between Cingular Wireless and Vodaphone. The prize: AT&T Wireless Services. The price: $41 billion. Checkout the players from our weekly scorecard of deals in the headlines.
4 minute read
January 28, 2008 | Connecticut Law Tribune

Firm Gears Up For High-Stakes Drug Lit

It can cost pharmaceutical companies hundreds of millions of dollars mdash; or more mdash; to develop a new prescription drug. Still, the investment can reap mind-boggling dividends.
6 minute read
February 19, 2013 | New York Law Journal

InMotion Honors Volunteers

Fifteen legal teams, law firms and individual lawyers were recently honored for their pro bono work helping low-income women for inMotion, a 20-year-old legal services nonprofit, over the past year.
2 minute read
January 23, 2006 | New Jersey Law Journal

Big Pharma's Big Leap

Authorized generics are becoming an increasingly popular tactic for brand-name drug makers facing an invalidated or expiring drug patent. But many in the generic camp fear that the long-term result will be a sharp reduction of future drug patent challenges. They argue that if generic drug makers are compelled to split the market - and the profits - during the 180-day exclusivity period, they'll have less incentive to challenge brand-name patents in the first place. The pot of gold just isn't as big.
10 minute read
May 01, 2013 | The American Lawyer

Big Wins

9 minute read
October 02, 2006 | National Law Journal

On the Move

5 minute read
April 17, 2006 | New York Law Journal

Newsbriefs

4 minute read
January 23, 2006 | The Legal Intelligencer

Authorized Generics A Clever Loophole To Hatch-Waxman

When Teva Pharmaceuticals Industries Ltd. secured the rights to market a generic version of the blockbuster drug Neurontin in 2004, it looked like the company was in for a period of robust good health.
10 minute read
August 17, 2007 | The Recorder

Qualcomm's Honor and Privilege

Day Casebeer partner Lee Patch is one of the Qualcomm lawyers facing sanctions for discovery errors. But an inquiring magistrate hasn't heard his story � or gotten any evidence about how those errors happened � because Qualcomm invoked attorney-client privilege.
5 minute read

More from ALM

More from ALM

Legal Speak is a weekly podcast that makes sense of what’s happening in the legal industry.

Resources

  • The Power of Online Reputation Management For Attorneys: A Critical Tool For Law Firms in 2025

    Brought to you by Erase.com

    Download Now

  • The Role of Evolving Support Structures in Optimizing Legal Talent

    Brought to you by BigHand

    Download Now

  • Corporate Monitorship Advisory Services

    Brought to you by HaystackID

    Download Now

  • AI-Powered Deposition and Medical Record Summaries: Low Risk, High Reward

    Brought to you by Parrot

    Download Now